These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31271827)

  • 41. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations.
    Das A; Alshareef M; Martinez Santos JL; Porto GBF; McDonald DG; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    Clin Transl Oncol; 2020 Nov; 22(11):2017-2025. PubMed ID: 32253706
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Knockdown of lncRNA BLACAT1 enhances radiosensitivity of head and neck squamous cell carcinoma cells by regulating PSEN1.
    Gou C; Han P; Li J; Gao L; Ji X; Dong F; Su Q; Zhang Y; Liu X
    Br J Radiol; 2020 Apr; 93(1108):20190154. PubMed ID: 31944856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo.
    Li R; Wang Q; Zhao Y; Zhu Y; Wang X
    Mol Biol Rep; 2024 Mar; 51(1):455. PubMed ID: 38536540
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
    Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
    Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells.
    Klieber N; Hildebrand LS; Faulhaber E; Symank J; Häck N; Härtl A; Fietkau R; Distel LV
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells.
    Dobler C; Jost T; Hecht M; Fietkau R; Distel L
    Cells; 2020 Sep; 9(9):. PubMed ID: 32883016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HPV + HNSCC-derived exosomal miR-9 induces macrophage M1 polarization and increases tumor radiosensitivity.
    Tong F; Mao X; Zhang S; Xie H; Yan B; Wang B; Sun J; Wei L
    Cancer Lett; 2020 May; 478():34-44. PubMed ID: 32120025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HPV, hypoxia and radiation response in head and neck cancer.
    Göttgens EL; Ostheimer C; Span PN; Bussink J; Hammond EM
    Br J Radiol; 2019 Jan; 92(1093):20180047. PubMed ID: 29493265
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
    Pesch AM; Hirsh NH; Chandler BC; Michmerhuizen AR; Ritter CL; Androsiglio MP; Wilder-Romans K; Liu M; Gersch CL; Larios JM; Pierce LJ; Rae JM; Speers CW
    Clin Cancer Res; 2020 Dec; 26(24):6568-6580. PubMed ID: 32967938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
    Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
    Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics and Impact of HPV-Associated p16 Expression on Head and Neck Squamous Cell Carcinoma in Thai Patients.
    Jiarpinitnun C; Larbcharoensub N; Pattaranutaporn P; Chureemas T; Juengsamarn J; Trachu N; Lukerak S; Chansriwong P; Ngamphaiboon N
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1679-1687. PubMed ID: 32592364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. pRb and CyclinD1 Complement p16 as Immunohistochemical Surrogate Markers of HPV Infection in Head and Neck Cancer.
    Dreyer JH; Hauck F; Barros MHM; Niedobitek G
    Appl Immunohistochem Mol Morphol; 2017; 25(5):366-373. PubMed ID: 26657876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.
    Berggren KL; Restrepo Cruz S; Hixon MD; Cowan AT; Keysar SB; Craig S; James J; Barry M; Ozbun MA; Jimeno A; McCance DJ; Beswick EJ; Gan GN
    Oncogene; 2019 Nov; 38(48):7329-7341. PubMed ID: 31417185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells.
    Storch K; Cordes N
    Int J Oncol; 2016 Jan; 48(1):191-8. PubMed ID: 26573875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.
    Rampias T; Pectasides E; Prasad M; Sasaki C; Gouveris P; Dimou A; Kountourakis P; Perisanidis C; Burtness B; Zaramboukas T; Rimm D; Fountzilas G; Psyrri A
    Ann Oncol; 2013 Aug; 24(8):2124-31. PubMed ID: 23406730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.